LifeStance Health Group, Inc. (LFST) saw its stock soar 10.00% in pre-market trading following the release of its second-quarter 2025 financial results, which surpassed analysts' expectations across key metrics.
The company reported Q2 revenue of $345.3 million, slightly above the IBES estimate of $345.2 million. More impressively, LifeStance's net income for the quarter came in at a loss of $3.8 million, significantly better than the expected loss of $9.87 million. The adjusted EBITDA for Q2 stood at $34 million, outperforming the IBES estimate of $31.1 million.
Adding to the positive sentiment, LifeStance provided an encouraging outlook for the third quarter of 2025. The company projects Q3 revenue between $345-365 million and adjusted EBITDA in the range of $33-39 million. This forward-looking guidance suggests continued growth and improved profitability, likely contributing to investors' enthusiasm and the subsequent pre-market stock surge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.